×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TARA – protara therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TARA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
11:50 pm
tara
Protara Announces Pricing of $75 Million Public Offering [Yahoo! Finance]
Medium
Report
Protara Announces Pricing of $75 Million Public Offering [Yahoo! Finance]
12/4
10:03 pm
tara
Protara Announces Pricing of $75 Million Public Offering
Medium
Report
Protara Announces Pricing of $75 Million Public Offering
12/4
04:57 pm
tara
Protara Announces Proposed Public Offering [Yahoo! Finance]
Medium
Report
Protara Announces Proposed Public Offering [Yahoo! Finance]
12/4
04:15 pm
tara
Protara Announces Proposed Public Offering
Medium
Report
Protara Announces Proposed Public Offering
12/4
07:33 am
tara
Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]
Medium
Report
Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]
12/3
02:19 pm
tara
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Low
Report
Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
12/3
08:00 am
tara
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Medium
Report
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
12/1
05:32 pm
tara
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 [Yahoo! Finance]
High
Report
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
08:00 am
tara
protara therapeutics, inc.
BEAT
Report
8.9%
protara therapeutics, inc.
8/11/2025
08:00 am
tara
protara therapeutics, inc.
BEAT
Report
-1.0%
protara therapeutics, inc.
5/8/2025
08:00 am
tara
protara therapeutics, inc.
BEAT
Report
0.9%
protara therapeutics, inc.
Date
Time
Symbol
Headline
Impact
12/4
04:29 pm
tara
Form 424B5 Protara Therapeutics,
Medium
Report
Form 424B5 Protara Therapeutics,
12/3
08:09 am
tara
Form 8-K Protara Therapeutics, For: Dec 03
Medium
Report
Form 8-K Protara Therapeutics, For: Dec 03
11/19
09:16 am
tara
Form 8-K Protara Therapeutics, For: Nov 19
Medium
Report
Form 8-K Protara Therapeutics, For: Nov 19
11/14
11:58 am
tara
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: JANUS HENDERSON GROUP PLC
11/10
08:11 am
tara
Form 10-Q Protara Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Protara Therapeutics, For: Sep 30
11/10
08:05 am
tara
Form 8-K Protara Therapeutics, For: Nov 10
Medium
Report
Form 8-K Protara Therapeutics, For: Nov 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 8-K ArTara Therapeutics, For: Mar 18
14.2%
1/21 Form SC 13D ArTara Therapeutics, Filed by: Opaleye Management Inc. 12.8%
2/4 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.9%
3/30 Form 8-K ArTara Therapeutics, For: Mar 26 6.5%
4/21 Verona Pharma plc (NASDAQ: TARA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/11 Form 424B3 ArTara Therapeutics, 4.6%
4/2 ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 4.3%
1/15 Form S-8 ArTara Therapeutics, 3.7%
2/14 Form SC 13G/A ArTara Therapeutics, Filed by: INTERSOUTH PARTNERS VI LP 2.7%
4/23 Form DEF 14A ArTara Therapeutics, For: Jun 09 2.5%
1/21 Form SC 13D ArTara Therapeutics, Filed by: Opaleye Management Inc. 12.8%
2/4 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.9%
3/30 Form 8-K ArTara Therapeutics, For: Mar 26 6.5%
4/21 Verona Pharma plc (NASDAQ: TARA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/11 Form 424B3 ArTara Therapeutics, 4.6%
4/2 ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 4.3%
1/15 Form S-8 ArTara Therapeutics, 3.7%
2/14 Form SC 13G/A ArTara Therapeutics, Filed by: INTERSOUTH PARTNERS VI LP 2.7%
4/23 Form DEF 14A ArTara Therapeutics, For: Jun 09 2.5%
TOP News Decliners
2/21
Form SC 13G ArTara Therapeutics, Filed by: Ikarian Capital, LLC
-7.6%
4/9 Form SEC STAFF LETTER ArTara Therapeutics, -6.1%
3/20 Form 10-K ArTara Therapeutics, For: Dec 31 -4.6%
4/18 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. -4.5%
1/30 Form S-3 ArTara Therapeutics, -4.0%
1/13 Form 3 ArTara Therapeutics, For: Jan 09 Filed by: Opaleye, L.P. -3.6%
2/18 Form 4/A ArTara Therapeutics, For: Jan 09 Filed by: Shefferman Jesse -3.1%
1/27 Form SC 13D/A ArTara Therapeutics, Filed by: Opaleye Management Inc. -1.6%
1/16 Form SC 13G ArTara Therapeutics, Filed by: Wilson Donald R. Jr. -0.6%
4/9 Form SEC STAFF LETTER ArTara Therapeutics, -6.1%
3/20 Form 10-K ArTara Therapeutics, For: Dec 31 -4.6%
4/18 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. -4.5%
1/30 Form S-3 ArTara Therapeutics, -4.0%
1/13 Form 3 ArTara Therapeutics, For: Jan 09 Filed by: Opaleye, L.P. -3.6%
2/18 Form 4/A ArTara Therapeutics, For: Jan 09 Filed by: Shefferman Jesse -3.1%
1/27 Form SC 13D/A ArTara Therapeutics, Filed by: Opaleye Management Inc. -1.6%
1/16 Form SC 13G ArTara Therapeutics, Filed by: Wilson Donald R. Jr. -0.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: